Joost P. G. Sluijter

In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions.

Involvement of furin-like proprotein convertases in the arterial response to injury.

Vascular remodeling and protease inhibition--bench to bedside.

Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig.

Stem cells from in- or outside of the heart: isolation, characterization, and potential for myocardial tissue regeneration.

The potential of modulating small RNA activity in vivo.

Human cardiomyocyte progenitor cell-derived cardiomyocytes display a maturated electrical phenotype.

Platelet-lysate as an autologous alternative for fetal bovine serum in cardiovascular tissue engineering.

MicroRNA-1 and -499 regulate differentiation and proliferation in human-derived cardiomyocyte progenitor cells.

Foetal and adult cardiomyocyte progenitor cells have different developmental potential.

Hyperpolarization induces differentiation in human cardiomyocyte progenitor cells.

MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1.

Non-surgical stem cell delivery strategies and in vivo cell tracking to injured myocardium.

Environmental regulation of valvulogenesis: implications for tissue engineering.

Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease.

Sequential use of human-derived medium supplements favours cardiovascular tissue engineering.

Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells.

MicroRNA-214 inhibits angiogenesis by targeting Quaking and reducing angiogenic growth factor release.

Human cardiomyocyte progenitor cells: a short history of nearly everything.

MiR-155 inhibits cell migration of human cardiomyocyte progenitor cells (hCMPCs) via targeting of MMP-16.

Targeting cell death in the reperfused heart: pharmacological approaches for cardioprotection.

Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-reperfusion in vivo.

Transendocardial cell injection is not superior to intracoronary infusion in a porcine model of ischaemic cardiomyopathy: a study on delivery efficiency.

Early assessment of acute coronary syndromes in the emergency department: the potential diagnostic value of circulating microRNAs.

Increasing short-term cardiomyocyte progenitor cell (CMPC) survival by necrostatin-1 did not further preserve cardiac function.

Concise review: heart regeneration and the role of cardiac stem cells.

Concise review: Engineering myocardial tissue: the convergence of stem cells biology and tissue engineering technology.

Wnt/β-catenin signaling directs the regional expansion of first and second heart field-derived ventricular cardiomyocytes.

Circulating microRNA profiles for detection of peripheral arterial disease: small new biomarkers for cardiovascular disease.

Layer-specific radiofrequency ultrasound-based strain analysis in a porcine model of ischemic cardiomyopathy validated by a geometric model.

Sustained delivery of insulin-like growth factor-1/hepatocyte growth factor stimulates endogenous cardiac repair in the chronic infarcted pig heart.

Microvesicles and exosomes for intracardiac communication.

Expanding mouse ventricular cardiomyocytes through GSK-3 inhibition.

Inhibition of miR-25 improves cardiac contractility in the failing heart.

Novel therapeutic strategies for cardioprotection.

Targeted delivery of miRNA therapeutics for cardiovascular diseases: opportunities and challenges.

Different types of cultured human adult cardiac progenitor cells have a high degree of transcriptome similarity.

ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies.

Ultrasound and microbubble-induced local delivery of MicroRNA-based therapeutics.

Necrostatin-1 alleviates reperfusion injury following acute myocardial infarction in pigs.

Exosomal microRNA clusters are important for the therapeutic effect of cardiac progenitor cells.

Cardiac allograft vasculopathy: a donor or recipient induced pathology?

A snapshot of genetic and epigenetic basis of arrhythmia and heart failure.

MicroRNA Therapeutics for Cardiac Regeneration.

MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia through modulation of the Ras-MAPK pathway.

Epicardial application of cardiac progenitor cells in a 3D-printed gelatin/hyaluronic acid patch preserves cardiac function after myocardial infarction.

Gap junctional protein Cx43 is involved in the communication between extracellular vesicles and mammalian cells.

Increased local delivery of antagomir therapeutics to the rodent myocardium using ultrasound and microbubbles.

Xenotransplantation of Human Cardiomyocyte Progenitor Cells Does Not Improve Cardiac Function in a Porcine Model of Chronic Ischemic Heart Failure. Results from a Randomized, Blinded, Placebo Controlled Trial.

Cardiac Stem Cell Treatment in Myocardial Infarction: A Systematic Review and Meta-Analysis of Preclinical Studies.

Gelatin Microspheres as Vehicle for Cardiac Progenitor Cells Delivery to the Myocardium.

Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure.

Stem cell-based therapy: Improving myocardial cell delivery.

Sepsis-associated cardiac dysfunction is controlled by small RNA molecules.

Isolation of Pig Bone Marrow-Derived Mesenchymal Stem Cells.

Long non-coding RNAs in heart failure: an obvious lnc.

Circulating Extracellular Vesicles Contain miRNAs and are Released as Early Biomarkers for Cardiac Injury.

Responder Definition in Clinical Stem Cell Trials in Cardiology: Will the Real Responder Please Stand Up?

Exosomes from Cardiomyocyte Progenitor Cells and Mesenchymal Stem Cells Stimulate Angiogenesis Via EMMPRIN.

Presence of Cx43 in extracellular vesicles reduces the cardiotoxicity of the anti-tumour therapeutic approach with doxorubicin.

Modeling the Human Scarred Heart In Vitro: Toward New Tissue Engineered Models.

MicroRNAs: The Swing Voters in Vascular Disease Waiting for a Program.

In vitro 3D model and miRNA drug delivery to target calcific aortic valve disease.

Cardiac-released extracellular vesicles can activate endothelial cells.

Higher functionality of extracellular vesicles isolated using size-exclusion chromatography compared to ultracentrifugation.

Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.

Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart.

Engineered 3D Cardiac Fibrotic Tissue to Study Fibrotic Remodeling.

Melt Electrospinning Writing of Poly-Hydroxymethylglycolide-co-ε-Caprolactone-Based Scaffolds for Cardiac Tissue Engineering.

SCA1 Cells from the Heart Possess a Molecular Circadian Clock and Display Circadian Oscillations in Cellular Functions.

ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery.

Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply.

Cardiac Progenitor-Cell Derived Exosomes as Cell-Free Therapeutic for Cardiac Repair.

Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology.

Cre-dependent Cas9-expressing pigs enable efficient in vivo genome editing.

Complement 5a Receptor deficiency does not influence adverse cardiac remodeling after pressure-overload in mice.

Engineering CRISPR/Cpf1 with tRNA promotes genome editing capability in mammalian systems.

Engineering a 3D-Bioprinted Model of Human Heart Valve Disease Using Nanoindentation-Based Biomechanics.

Vascular extracellular vesicles in comorbidities of heart failure with preserved ejection fraction in men and women: The hidden players. A mini review.

MMISH: Multicolor microRNA hybridization for paraffin embedded samples.

Modelling inherited cardiac disease using human induced pluripotent stem cell-derived cardiomyocytes: progress, pitfalls, and potential.

Circular RNAs as Potential Theranostics in the Cardiovascular System.

Cardiac Progenitor Cell-Derived Extracellular Vesicles Reduce Infarct Size and Associate with Increased Cardiovascular Cell Proliferation.

Cardiomyocyte Progenitor Cells as a Functional Gene Delivery Vehicle for Long-Term Biological Pacing.

ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure.

Cathelicidin-related antimicrobial peptide protects against myocardial ischemia/reperfusion injury.

Anti-fibrotic Effects of Cardiac Progenitor Cells in a 3D-Model of Human Cardiac Fibrosis.

Drug Delivery with Extracellular Vesicles: From Imagination to Innovation.

miR-19a-3p containing exosomes improve function of ischaemic myocardium upon shock wave therapy.

Decellularized Extracellular Matrix Hydrogels as a Delivery Platform for MicroRNA and Extracellular Vesicle Therapeutics.

Increased circulating IgG levels, myocardial immune cells and IgG deposits support a role for an immune response in pre- and end-stage heart failure.

Injectable Supramolecular Ureidopyrimidinone Hydrogels Provide Sustained Release of Extracellular Vesicle Therapeutics.

Fiber Scaffold Patterning for Mending Hearts: 3D Organization Bringing the Next Step.

Polymeric siRNA gene delivery - transfection efficiency versus cytotoxicity.

Biofabrication of Cell-Derived Nanovesicles: A Potential Alternative to Extracellular Vesicles for Regenerative Medicine.

Potential of mesenchymal- and cardiac progenitor cells for therapeutic targeting of B-cells and antibody responses in end-stage heart failure.

Cardiomyocyte Specific Deletion of ADAR1 Causes Severe Cardiac Dysfunction and Increased Lethality.

Non-coding RNAs in Cardiac Regeneration.

Control of Angiogenesis via a VHL/miR-212/132 Axis.

The transverse aortic constriction heart failure animal model: a systematic review and meta-analysis.

Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function.

Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function.

Immunomodulation in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives.

Requirements for Proper Immunosuppressive Regimens to Limit Translational Failure of Cardiac Cell Therapy in Preclinical Large Animal Models.

Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart.

Loss of miR-132/212 Has No Long-Term Beneficial Effect on Cardiac Function After Permanent Coronary Occlusion in Mice.

Wnt Activation and Reduced Cell-Cell Contact Synergistically Induce Massive Expansion of Functional Human iPSC-Derived Cardiomyocytes.

Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart.

Current Perspectives on Inflammation in Cardiovascular Disease; from Biomarker to Therapy.

Repairing the heart: State-of the art delivery strategies for biological therapeutics.

Extracellular Vesicle-Associated Proteins in Tissue Repair.

Intercellular Communication in the Heart: Therapeutic Opportunities for Cardiac Ischemia.

Cardiac circadian rhythms in time and space: The future is in 4D.

Damage-Associated Molecular Patterns in Myocardial Infarction and Heart Transplantation: The Road to Translational Success.

Advanced Modeling to Study the Paradox of Mechanically Induced Cardiac Fibrosis.

Angiotensin II-induced muscle atrophy via PPARγ suppression is mediated by miR-29b.

Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes.

miR-132/212 Impairs Cardiomyocytes Contractility in the Failing Heart by Suppressing SERCA2a.

Unfolded Protein Response as a Compensatory Mechanism and Potential Therapeutic Target in PLN R14del Cardiomyopathy.

A Roadmap to Cardiac Tissue-Engineered Construct Preservation: Insights from Cells, Tissues, and Organs.

Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI).

ADAR2 increases in exercised heart and protects against myocardial infarction and doxorubicin-induced cardiotoxicity.

Targeting Inflammation after Myocardial Infarction: A Therapeutic Opportunity for Extracellular Vesicles?

Neutral Effects of Combined Treatment With GLP-1R Agonist Exenatide and MR Antagonist Potassium Canrenoate on Cardiac Function in Porcine and Murine Chronic Heart Failure Models.

Functional siRNA Delivery by Extracellular Vesicle-Liposome Hybrid Nanoparticles.

Percutaneous Intracoronary Delivery of Plasma Extracellular Vesicles Protects the Myocardium Against Ischemia-Reperfusion Injury in Canis.

Circadian rhythms in ischaemic heart disease: key aspects for preclinical and translational research: position paper of the ESC working group on cellular biology of the heart.

Controlled delivery of gold nanoparticle-coupled miRNA therapeutics an injectable self-healing hydrogel.

Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.

Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles.

Sarcomere Disassembly and Transfection Efficiency in Proliferating Human iPSC-Derived Cardiomyocytes.

Methods for the identification and characterization of extracellular vesicles in cardiovascular studies - from exosomes to microvesicles.

Pirfenidone Has Anti-fibrotic Effects in a Tissue-Engineered Model of Human Cardiac Fibrosis.

Extracellular vesicles enclosed-miR-421 suppresses air pollution (PM )-induced cardiac dysfunction via ACE2 signalling.

Circadian Dependence of the Acute Immune Response to Myocardial Infarction.

Long COVID and the cardiovascular system - elucidating causes and cellular mechanisms in order to develop targeted diagnostic and therapeutic strategies: A joint Scientific Statement of the ESC Working Groups on Cellular Biology of the Heart and Myocardial & Pericardial Diseases.

Clinical Phenotypes of Heart Failure With Preserved Ejection Fraction to Select Preclinical Animal Models.

Inhibition of HIPK2 protects stress-induced pathological cardiac remodeling.

METTL14 is required for exercise-induced cardiac hypertrophy and protects against myocardial ischemia-reperfusion injury.

Cardiac fibroblasts and mechanosensation in heart development, health and disease.

Enabling Precision Medicine with CRISPR-Cas Genome Editing Technology: A Translational Perspective.

Evaluation and manipulation of tissue and cellular distribution of cardiac progenitor cell-derived extracellular vesicles.

NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction.

Small molecule-mediated rapid maturation of human induced pluripotent stem cell-derived cardiomyocytes.

Elevated Plasma Immunoglobulin Levels Prior to Heart Transplantation Are Associated with Poor Post-Transplantation Survival.

TOP-EVs: Technology of Protein delivery through Extracellular Vesicles is a versatile platform for intracellular protein delivery.